Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2016 Financial Results
Nov 03, 2016 11:30 am UTC| Business
RADNOR, Pa., Nov. 03, 2016 -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and other neuropsychiatric disorders,...
Nov 03, 2016 11:30 am UTC| Business
CORALVILLE, Iowa, Nov. 03, 2016 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced it has appealed the...
Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis
Nov 03, 2016 11:30 am UTC| Business
SAN DIEGO, Nov. 03, 2016 -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced the initiation of ENCORE-PH (PH for Portal Hypertension), a randomized, double-blind, placebo-controlled, Phase 2b clinical trial...
Repligen Reports Third Quarter 2016 Financial Results
Nov 03, 2016 11:30 am UTC| Business
WALTHAM, Mass., Nov. 03, 2016 -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the third quarter ended September 30,...
Excel Corporation Closes $25 Million Credit Facility
Nov 03, 2016 11:30 am UTC| Business
IRVING, Texas, Nov. 03, 2016 -- Excel Corporation (OTCQB:EXCC), a leading provider of integrated financial and transaction processing services to merchants throughout the United States today announced that it secured a...
MSG Networks Inc. Reports Fiscal 2017 First Quarter Results
Nov 03, 2016 11:30 am UTC| Business
Fiscal 2017 first quarter revenues of $153.6 millionFiscal 2017 first quarter operating income of $74.5 millionFiscal 2017 first quarter adjusted operating income of $78.9 million NEW YORK, Nov. 03, 2016 -- MSG...
Minerva Neurosciences Reports Third Quarter 2016 Financial Results and Business Updates
Nov 03, 2016 11:30 am UTC| Business
WALTHAM, Mass., Nov. 03, 2016 -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today...